胎儿镜激光消融与标准管理治疗II型和III型血管前置的比较
本研究比较了妊娠晚期胎儿镜激光消融(FLA)与标准管理(SM)对II型或III型血管前置(VP)的母婴结局。结果显示FLA组分娩孕周更晚(中位36.0周 vs 34.4周),阴道分娩率62.9%,产妇产前住院时间更短,新生儿输血需求更低。
要点
- FLA组分娩孕周中位36.0周,显著晚于SM组的34.4周(P<0.001)。
- FLA组阴道分娩率62.9%,产妇产前住院中位1天,短于SM组的16天。
- FLA组新生儿输血需求0%,低于SM组的18.8%(P=0.009)。
核心结论
- 妊娠晚期FLA可作为II型或III型VP的替代管理方案,与更晚的分娩孕周和阴道分娩可能性相关。
主要发现
- FLA组分分娩孕周中位36.0周(IQR 35.0-37.6),SM组34.4周(IQR 33.4-35.0),P<0.001。
- FLA组阴道分娩率62.9%。
- FLA组产妇产前住院中位1天(IQR 0-3),SM组16天(IQR 7-23),P<0.001。
- SM组早产风险高于FLA组(风险比0.24,95%CI 0.14-0.44)。
- FLA组新生儿输血需求0%,SM组18.8%,P=0.009。
临床怎么用
- 对于产前诊断的II型或III型VP,FLA可考虑作为标准管理的替代方案,以延长孕周并提高阴道分娩机会。
局限性
- SM组为单中心回顾性选取,FLA组为前瞻性随访,可能存在选择偏倚。
- 样本量有限,需进一步研究评估FLA疗效及母婴结局的潜在获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The standard management (SM) for vasa previa (VP) includes antepartum inpatient admission at 28-32 weeks' gestation followed by Cesarean delivery at 34-37 weeks. Case reports and case series have reported on fetoscopic laser ablation (FLA) as an alternative management approach for Types-II and -III VP. This study compared maternal and neonatal outcomes in patients with Type-II or -III VP who underwent third-trimester FLA with those who underwent SM. METHODS: This was a cohort study of all antenatally diagnosed cases of Type-II or -III VP identified by ultrasound at, or referred to, two large referral centers in the USA between September 2016 and December 2023. Patients undergoing elective FLA were prospectively followed in both centers, while patients in the SM cohort were selected retrospectively from a single center. The primary outcome was gestational age at delivery. Comparative analysis was performed between SM and FLA cohorts. RESULTS: There were 67 singleton pregnancies complicated by Type-II or -III VP, of which 35 (52.2%) underwent FLA. There were no differences in baseline demographics between the two cohorts. The median gestational age at delivery was 36.0 (interquartile range (IQR), 35.0-37.6) weeks in the FLA cohort and 34.4 (IQR, 33.4-35.0) weeks in the SM cohort (P < 0.001). The rate of vaginal delivery in the FLA cohort was 62.9%. Individuals who underwent FLA had a shorter maternal antepartum stay than did those with SM (median, 1 (IQR, 0-3) days vs 16 (IQR, 7-23) days; P < 0.001). The probability of preterm delivery was higher with SM than with FLA (hazard ratio, 0.24 (95% CI, 0.14-0.44)). The need for neonatal blood transfusion was lower in the FLA cohort than in the SM cohort (0% vs 18.8%; P = 0.009). CONCLUSIONS: Third-trimester FLA offers an alternative to SM for pregnancies complicated by Type-II or -III VP, as it is associated with delivery at a later gestational age and facilitates the option of vaginal delivery. Further research is needed to assess the efficacy of FLA and to provide adequate power to evaluate the potential benefits for both maternal and neonatal outcomes. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Backley S, Chmait RH, Bergh EP, et al. Fetoscopic laser ablation vs standard management for Type-II and Type-III vasa previa. Ultrasound Obstet Gynecol. 2026. PMID: 41643072. doi:10.1002/uog.70186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。